Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 13.6% in February

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a large decline in short interest in February. As of February 15th, there was short interest totalling 91,300 shares, a decline of 13.6% from the January 31st total of 105,700 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average trading volume of 142,000 shares, the days-to-cover ratio is currently 0.6 days.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN XTNT opened at $0.50 on Thursday. The firm has a 50 day moving average price of $0.52. Xtant Medical has a 52 week low of $0.33 and a 52 week high of $1.24. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The company has a market cap of $69.49 million, a PE ratio of -3.85 and a beta of 0.35.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC lifted its position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 515,006 shares of the medical device company’s stock after purchasing an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.